Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy

about

Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy

Item

http://www.wikidata.org/entity/Q36104325

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Lenalidomide in the treatment ...... solidation/maintenance therapy

@ast

Lenalidomide in the treatment ...... solidation/maintenance therapy

@en

type

Item

label

Lenalidomide in the treatment ...... solidation/maintenance therapy

@ast

Lenalidomide in the treatment ...... solidation/maintenance therapy

@en

prefLabel

Lenalidomide in the treatment ...... solidation/maintenance therapy

@ast

Lenalidomide in the treatment ...... solidation/maintenance therapy

@en

P1476

Lenalidomide in the treatment ...... solidation/maintenance therapy

@en

P2093

Antonio Palumbo

http://www.w3.org/2001/XMLSchema#string

Barbara Lupo

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.

P304

906247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/906247

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230566091

http://www.w3.org/2001/XMLSchema#string

P698

22829835

http://www.w3.org/2001/XMLSchema#string

P932

3400298

http://www.w3.org/2001/XMLSchema#string